Are Classification Criteria for IgG4-RD Now Possible? The Concept of IgG4-Related Disease and Proposal of Comprehensive Diagnostic Criteria in Japan [PDF]
, 2012 Kazuichi Okazaki, Hisanori Umehara
openalex +1 more source
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang +8 more
wiley +1 more source
IgG4-related disease: case report and literature review [PDF]
, 2015 Abo-Helo Nizar, Elias Toubi
openalex +1 more source
IgG4-related ophthalmic disease masquerading as ciliary body tumors and scleritis in both eyes: a case report [PDF]
, 2023 Jiayue Ma +5 more
openalex +1 more source
European Journal of Haematology, Volume 116, Issue 2, Page 116-128, February 2026.ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli +5 more
wiley +1 more source
Soft Tissue Rosai-Dorfman Disease With Features of IgG4-Related Disease: A Case Report and Review of Literature [PDF]
, 2014 Siddharth Bhattacharyya +4 more
openalex +1 more source
IgG4-Related Diseases Involving Bilateral Renal Pelvises Successfully Treated with Steroid Therapy
, 2023 Illyoung Seo, Youri Kim
openalex +1 more source
Complete remission of central nervous system manifestations of IgG4-related disease with rituximab – a case report [PDF]
, 2023 Aleksi J. Sihvonen +4 more
openalex +1 more source
European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta +10 more
wiley +1 more source